ISSCR News
ISSCR Develops Roadmap to Accelerate Pluripotent Stem Cell-Derived Therapies to Patients
The International Society for Stem Cell Research (ISSCR) today announced the upcoming release of “Charting the Translational Pathway: ISSCR Best Practices for the Development of Pluripotent Stem Cell (PSC)-Derived Therapies,” a new paper highlighting some of the most critical aspects of the ISSCR’s breakthrough interactive resource designed to transform how PSC-derived therapies are developed, evaluated, and advanced toward clinical and commercial success. The paper was published today in Stem Cell Reports.
The ISSCR Launches Roadmap for Developing Pluripotent Stem Cell-Derived Therapies
New Guidance Aims to Enhance the Translation of Cell Therapies
The International Society for Stem Cell Research (ISSCR) is proud to announce the release of Best Practices for the Development of Pluripotent Stem Cell-Derived Cellular Therapies, a comprehensive new resource designed to accelerate the translation of human pluripotent stem cell (PSC)-derived therapies into clinical trials and commercial use.
Developed by leading international experts in cell therapy, this groundbreaking document outlines the key principles and decision points required to develop safe, effective, and regulatory compliant PSC-derived products. Organized into seven sections, the guidance offers jurisdictionally neutral information on topics ranging from PSC line selection and raw material use to regulatory considerations, preclinical studies, and clinical trials.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .